Clinical trials: Resistant Depression, Treatment
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Depression Depressed Phase
Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC.
- Trial name
- FLARE (NCT06986460)
- Testing
- MagPro X100/R30 stimulator, Cool-B70 coil
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Tyler Kaster
Treatment-Resistant Depression, Depressive Disorder
Stereotactic Radiotherapy Treatment for Treatment-Resistant Depression
This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression
- Trial name
- NCT07274917
- Testing
- ZAP-X
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Capital Medical University
Treatment Resistant Depression
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
- Trial name
- NCT01687478
- Testing
- Olanzapine, Fluoxetine
- Where
- 11 sites in China
- Volunteers
- 176 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Treatment-Resistant
Adaptive tDCS for Treatment-Resistant MDD
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD).
- Trial name
- NCT02942368
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Deep Brain Stimulation to Relieve Depression
This is an open label study with a sample size of 6 to develop deep brain stimulation of the subcallosal cingulate white matter(SCCWM) for late life depression using an experimental medicine approach in which the investigators…
- Trial name
- DRIVER (NCT02889250)
- Testing
- Medtronic Activa SC DBS, Lead Model 3387
- Sponsor
- Jordan F. Karp
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
This is a study that will recruit patients from the neurosurgery clinic and the regular TMS clinic. It's a smaller study designed to collect brain imaging pre-treatment and then use image guided TMS to treat patient with a one…
- Trial name
- NCT05813093
- Testing
- rTMS
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Sunnybrook Health Sciences Centre
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Treatment Resistant Depression
Accelerated High-dose Sequential Bilateral Theta Burst Stimulation for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) and Theta burst stimulation (TBS) are approved by the US. Food and Drug administration (FDA) for the treatment of refractory major depression.
- Trial name
- NCT05811104
- Testing
- Sequential bilateral theta burst stimulation
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Depression
Neural Circuit Biomarkers of Transcranial Magnetic Stimulation Study
This study is currently recruiting Veterans only. The objective of this observational study is to test whether neuroimaging biomarkers of repetitive transcranial magnetic stimulation (TMS) can be prospectively replicated in a…
- Trial name
- NCT04663841
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Pharmacoresistant Depression
Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Clinical Study Coupled With Positon Emission Tomography (PET)
Repetitive transcranial magnetic stimulation (TMS) is an emergent non-invasive treatment for treatment resistant depression (TRD).
- Trial name
- NCT02559466
- Testing
- Transcranial Magnetic Stimulation (TMS - ) - MagPro®, Positon Emission Tomography (PET) - Discovery 710®
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Major Depressive Disorder
Mitochondrial Function After Ketamine
The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression. the Research Questions are 1.
- Trial name
- NCT07399756
- Testing
- S (+) Ketamine
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Depression, Bipolar Depression
Efficacy of Convulsive Therapies During Continuation
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.
- Conditions
- Depression, Bipolar Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CORRECT-C (NCT03711019)
- Testing
- Magnetic Seizure Therapy (MST), RUL-UB ECT, Bitemporal ECT
- Where
- 3 sites in Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Depression, Type 1 Diabetes
Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes
This study is a pilot behavioral intervention trial, designed to initially examine cognitive behavioral therapy for medical adherence and depression (CBT-AD) in patients with depression and poorly controlled type 1 diabetes.
- Trial name
- NCT01527981
- Testing
- Cognitive behavioral therapy for adherence and depression
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Depression
taVNS or TMS or Both for Depression
The purpose of the research is to test out a combined treatment for depression where the investigators stimulate a nerve in the ear while at the same time stimulate the brain with magnets.
- Trial name
- NCT05725239
- Testing
- Vagus Nerve Stimulation, Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Suicidal Ideation, Major Depressive Disorder
N2O for Acute Suicidality and Depression in the ED
Investigators are conducting this double-blind, randomized control trial (RCT), to compare inhaled N2O+ treatment as usual (TAU) versus inhaled placebo+TAU; demonstrating the feasibility and tolerability of the intervention in an…
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05710887
- Testing
- Nitrous oxide gas for inhalation
- Where
- United States
- Sponsor
- University of Chicago
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Depression, Major Depression
Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients
The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.
- Trial name
- EffECT (NCT00437385)
- Testing
- TCAs, SSRIs, NARIs, SNRIs, Lithium, Electroconvulsive therapy, Cognitive behavioral group therapy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Charite University, Berlin, Germany
Depression
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression.
- Trial name
- NCT01128452
- Testing
- EVT 101
- Where
- 14 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC